Analytical Data
-
基因名
CDKN2C
-
简介
The CDKN2C protein (also known as p18) interacts strongly with CDK6 and weakly with CDK4. Its functional effects inhibit cell growth and proliferation and are significantly related to the presence of endogenous retinoblastoma protein RB. CDKN2C Protein, Human (His) is the recombinant human-derived CDKN2C protein, expressed by E. coli , with N-6*His labeled tag.
- Application
-
别名
rHuCyclin-dependent kinase 4 inhibitor C/CDKN2C, His; Cyclin-Dependent Kinase 4 Inhibitor C; Cyclin-Dependent Kinase 6 Inhibitor; p18-INK4c; p18-INK6; CDKN2C; CDKN6
-
种属
Human
-
表达系统
E. coli
-
标签
N-6*His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P42773
-
表达区间
M1-Q168
-
蛋白长度
Full Length
-
分子量
17.0 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDKN2C, a member of the CDK inhibitor family, plays a critical role in cell cycle regulation by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6), thereby preventing the progression from the G1 phase to the S phase of the cell cycle. Mutations and deletions in the CDKN2C gene have been implicated in various cancers, particularly in gliomas and certain types of leukemia, underscoring its significance as a tumor suppressor. Recent studies have focused on the role of CDKN2C in maintaining genomic stability and its interactions with other oncogenic pathways, revealing its potential as a therapeutic target. The recombinant protein of CDKN2C provides a valuable tool for further exploring its functional mechanisms, interactions, and effects on cell proliferation and apoptosis. This research is essential for understanding the complexities of tumorigenesis and developing targeted therapies that could enhance patient outcomes in cancers associated with CDKN2C dysregulation. Through the study of CDKN2C recombinant protein, scientists aim to elucidate the molecular pathways that govern cell cycle control and cancer progression, paving the way for innovative treatment strategies that leverage the tumor-suppressive properties of this vital protein.
